MICVO Shows Phase I Activity in Recurrent Head and Neck Cancer

Evidence Company disclosure · Discovery September 9, 2026 · Importance 4/5 · Direction Positive Summary Pyxis Oncology reported updated Phase I monotherapy data for micvotabart pelidotin, or MICVO, in second-line or later recurrent or metastatic head and neck squamous-cell carcinoma. Among 33 efficacy-evaluable patients treated…